Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Disease progression and outcome measures in spinobulbar muscular atrophy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Neuroinflammatory markers associate with cognitive decline after major surgery: findings of an explorative study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Early Intrathecal T Helper 17.1 Cell Activity in Huntington Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. POPDC3 Gene Variants Associate with a New Form of Limb Girdle Muscular Dystrophy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Soluble ST2 links inflammation to outcome after subarachnoid hemorrhage

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Autism and developmental disability caused by KCNQ3 gain-of-function variants

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Impaired lipolysis in propionic acidemia: A new metabolic myopathy?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Absence of p.R50X Pygm read-through in McArdle disease cellular models

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. European muscle MRI study in limb girdle muscular dystrophy type R1/2A (LGMDR1/LGMD2A)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Growth and differentiation factor 15 as a biomarker for mitochondrial myopathy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVE: Spinal and bulbar muscular atrophy (SBMA) is a slowly progressive disease with weakness of bulbar and extremity muscles. There is no curative treatment for the disease, but several clinical trials have been conducted over the past years. The results from these trials have uncovered a great need to develop quantitative, reliable outcome measures. In this study, we prospectively investigated disease progression over 18 months in 29 patients with genetically confirmed SBMA, using quantitative outcome measures, including Dixon magnetic resonance imaging (MRI).

METHODS: We used MRI to assess changes in muscle fat content and stationary dynamometry to assess changes in muscle strength. Disease progression was also investigated with the SBMA functional rating scale, bulbar rating scale, 6-minute walk test, and blood samples, among others.

RESULTS: Mean muscle fat content, muscle strength in knee extensors, handgrip strength, walking distance, and creatinine levels changed significantly. Mean muscle fat content increased by 2 ± 1.25%, and knee extension strength decreased from 83 ± 60 to 76 ± 56Nm, handgrip strength from 31 ± 13 to 29 ± 13kg, walking distance from 362 ± 216 to 336 ± 219m, and creatinine level from 58 ± 21 to 54 ± 20 μmol/l. Functional rating scores did not change.

INTERPRETATION: The present study demonstrates a slow and steady disease progression in SBMA. Dixon MRI detected increases in muscle fat content in all investigated muscles and is therefore a suitable candidate for an outcome measure in natural history or treatment studies in SBMA. The 6-minute walk test and handgrip strength also seem to be reliable outcome measures for SBMA. Ann Neurol 2018;84:762-773.

OriginalsprogEngelsk
TidsskriftAnnals of Neurology
Vol/bind84
Udgave nummer5
Sider (fra-til)754-765
Antal sider12
ISSN0364-5134
DOI
StatusUdgivet - nov. 2018

ID: 55677579